The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression
Abstract
Background: The importance of protein glycosylation in regulating lipid metabolism is becoming increasingly apparent. We set out to further investigate this by studying patients with type I congenital disorders of glycosylation (CDGs) with defective N-glycosylation. Methods: We studied 29 patients with the 2 most prevalent types of type I CDG, ALG6 (asparagine-linked glycosylation protein 6)–deficiency CDG and PMM2 (phosphomannomutase 2)–deficiency CDG, and 23 first- and second-degree relatives with a heterozygous mutation and measured plasma cholesterol levels. Low-density lipoprotein (LDL) metabolism was studied in 3 cell models—gene silencing in HepG2 cells, patient fibroblasts, and patient hepatocyte-like cells derived from induced pluripotent stem cells—by measuring apolipoprotein B production and secretion, LDL receptor expression and membrane abundance, and LDL particle uptake. Furthermore, SREBP2 (sterol regulatory element-binding protein 2) protein expression and activation and endoplasmic reticulum stress markers were studied. Results: We report hypobetalipoproteinemia (LDL cholesterol [LDL-C] and apolipoprotein B below the fifth percentile) in a large cohort of patients with type I CDG (mean age, 9 years), together with reduced LDL-C and apolipoprotein B in clinically unaffected heterozygous relatives (mean age, 46 years), compared with 2 separate sets of age- and sex-matched control subjects. ALG6 and PMM2 deficiency led to markedly increased LDL uptake as a result of increased cell surface LDL receptor abundance. Mechanistically, this outcome was driven by increased SREBP2 protein expression accompanied by amplified target gene expression, resulting in higher LDL receptor protein levels. Endoplasmic reticulum stress was not found to be a major mediator. Conclusions: Our study establishes N-glycosylation as an important regulator of LDL metabolism. Given that LDL-C was also reduced in a group of clinically unaffected heterozygotes, we propose that increasing LDL receptor–mediated cholesterol clearance by targeting N-glycosylation in the LDL pathway may represent a novel therapeutic strategy to reduce LDL-C and cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These mutations can result from misfolding in the ER or from point mutations at key sites for glycosylation, such as has been recently observed in human N-glycosylation mutants88.”
From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Research works printed but not linked: 45
- 10.1097/MOL.0000000000000461 · DOI
- 10.1016/j.cell.2006.08.019 · DOI · Paper page
- 10.1038/ng.291 · DOI · Paper page
- 10.1016/j.cmet.2011.11.005 · DOI
- 10.1074/jbc.M110.156950 · DOI
- 10.1016/j.cmet.2016.07.012 · DOI
- 10.1016/j.ajhg.2013.10.024 · DOI · Paper page
- 10.1111/j.1749-6632.2010.05840.x · DOI · Paper page
- 10.1007/s10545-014-9720-9 · DOI
- 10.1016/j.bbadis.2008.11.012 · DOI
- 10.1016/S0140-6736(87)91287-6 · DOI · Paper page
- 10.1016/S0387-7604(12)80276-2 · DOI
- 10.1007/BF00873975 · DOI
- 10.1007/s10545-011-9370-0 · DOI
- 10.1074/jbc.M203285200 · DOI
- 10.1016/S0925-4439(99)00072-1 · DOI
- 10.1002/hep.25871 · DOI
- 10.1093/eurheartj/ehs472 · DOI
- 10.1172/JCI32752 · DOI · Paper page
- 10.1155/2012/610741 · DOI
- 10.1074/jbc.M410302200 · DOI · Paper page
- 10.1007/s00018-005-4473-0 · DOI
- 10.1023/A:1013944308881 · DOI
- 10.1161/ATVBAHA.108.181859 · DOI
- 10.1074/jbc.272.33.20427 · DOI · Paper page
- 10.1016/S0021-9258(19)42341-7 · DOI · Paper page
- 10.1073/pnas.93.11.5437 · DOI
- 10.1074/jbc.M408235200 · DOI · Paper page
- 10.1172/JCI11596 · DOI · Paper page
- 10.1074/jbc.M116.744235 · DOI
- 10.1016/s0092-8674(00)80213-5 · DOI · Paper page
- 10.1093/clinchem/42.4.515 · DOI · Paper page
- 10.1161/ATVBAHA.109.194191 · DOI
- 10.1074/jbc.M606495200 · DOI · Paper page
- 10.1016/S0022-2275(20)32192-1 · DOI
- 10.1042/0264-6021:3530493 · doi:10.1042/0264-6021:3530493
- 10.1194/jlr.m200077-jlr200 · DOI
- 10.1073/pnas.262669399 · DOI
- van den Boogert, MAW, Kuil, SD, Hovingh, GK, Motazacker, MM, Levels, JHM, Dallinga-Thie, GM, Kuivenhoven, JA, Wevers, R, Stroes, ESG, Lefeber, DJ, et al. Genetic defects in protein glycosylation as a cause of dyslipidemia. Poster presented at: American Heart Association Scientific Sessions in the Best of Basic Science Session; November 16–20, 2013; Dallas, TX.
- 10.1016/j.ajhg.2015.12.010 · DOI
- 10.1016/j.ajhg.2015.12.011 · DOI
- 10.1038/emboj.2013.79 · DOI · Paper page
- Jaeken, J, Matthijs, G, Carchon, H, Van Schaftingen, E. 2001 defects of N-glycan synthesis. Scriver, C, Beaudet, A, Sly, WS, Valle, D, eds. In: The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill:1601–1622
- 10.1126/science.1235681 · DOI · Paper page
- 10.1038/nj7661-127a · doi:10.1038/nj7661-127a
Cited by
Pathophysiology of Atherosclerosis
Jebari-Benslaiman, S., Galicia-García, U., Larrea-Sebal, A., Olaetxea, J. R., Alloza, I., Vandenbroeck, K., Benito-Vicente, A., & Martín, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063346 · Cited by 1,010
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Pathways and Molecular Mechanisms Governing LDL Receptor Regulation
Schmidt, H. M., Jarrett, K. E., de Aguiar Vallim, T. Q., & Tarling, E. J. (2025) · Circulation Research · doi:10.1161/circresaha.124.323578 · Cited by 33
Differences in Recycling of Apolipoprotein E3 and E4—LDL Receptor Complexes—A Mechanistic Hypothesis
Kim, M., & Bezprozvanny, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095030 · Cited by 11
Metadata
- Authors
- van den Boogert, M. A. W., Larsen, L. E., Ali, L., Kuil, S. D., Chong, P. L. W., Loregger, A., Kroon, J., Schnitzler, J. G., Schimmel, A. W. M., Peter, J., Levels, J. H. M., Steenbergen, G., Morava, E., Dallinga-Thie, G. M., Wevers, R. A., Kuivenhoven, J. A., Hand, N. J., Zelcer, N., Rader, D. J., Stroes, E. S. G., Lefeber, D. J., & Holleboom, A. G.
- Affiliations
- Departments of Vascular Medicine (M.A.W.v.d.B., J.K., G.M.D.-T., E.S.G.S., A.G.H.), Amsterdam University Medical Centers, location AMC, The Netherlands.
- Experimental Vascular Medicine (M.A.W.v.d.B., L.E.L., L.A., P.L.W.C., J.K., J.G.S., A.W.M.S., J.P., J.H.M.L., G.M.D.-T.), Amsterdam University Medical Centers, location AMC, The Netherlands.
- Department of Laboratory Medicine, Translational Metabolic Laboratory (S.D.K., G.S., R.A.W., D.J.L.), Radboud University Medical Center, Nijmegen, The Netherlands.
- Medical Biochemistry (A.L., N.Z.), Amsterdam University Medical Centers, location AMC, The Netherlands.
- Department of Clinical Genomics, Mayo Clinic, Rochester, MN (E.M.).
- Department of Pediatrics, Section Molecular Genetics, University Medical Center Groningen, University of Groningen, The Netherlands (J.A.K.)
- Department of Genetics and Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (L.E.L., P.L.W.C., N.J.H., D.J.R.).
- Venue
- Circulation
- Published
- 2019-07-23
- Volume
- 140
- Issue
- 4
- Pages
- 280-292
- ISSN
- 0009-7322
- 1524-4539
- Cited by
- 38
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. https://app.cochat.ai/papers/10.1161/circulationaha.118.036484
- The paper
- van den Boogert, M. A. W., Larsen, L. E., Ali, L., Kuil, S. D., Chong, P. L. W., Loregger, A., Kroon, J., Schnitzler, J. G., Schimmel, A. W. M., Peter, J., Levels, J. H. M., Steenbergen, G., Morava, E., Dallinga-Thie, G. M., Wevers, R. A., Kuivenhoven, J. A., Hand, N. J., Zelcer, N., Rader, D. J., . . . Holleboom, A. G. (2019). N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. Circulation. https://doi.org/10.1161/circulationaha.118.036484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.